SAB Biotherapeutics (SABS) Accumulated Expenses (2020 - 2026)

SAB Biotherapeutics has reported Accumulated Expenses for 7 years, with the latest figure at $2.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 13059.24% year-over-year to $2.9 million; the trailing twelve-month figure through Mar 2026 stood at $2.9 million (up 13059.24% YoY), and the FY2025 full-year result was $5.0 million, up 22339.24% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $2.9 million, down from $5.0 million in the prior quarter.
• The five-year high for Accumulated Expenses was $5.1 million in Q2 2025, with the low at $8192.0 in Q4 2022.
• Historically, Accumulated Expenses has averaged $1.1 million across 5 years, with a median of $274104.0 in 2022.
• The largest YoY upside for Accumulated Expenses was 22339.24% in 2025 against a maximum downside of 98.85% in 2025.
• SAB Biotherapeutics' Accumulated Expenses stood at $8192.0 in 2022, then soared by 852.09% to $77995.0 in 2023, then plunged by 71.23% to $22443.0 in 2024, then soared by 22339.24% to $5.0 million in 2025, then slumped by 42.52% to $2.9 million in 2026.
• The last three Accumulated Expenses figures came in at $2.9 million (Q1 2026), $5.0 million (Q4 2025), and $21311.0 (Q3 2025), per Business Quant data.